Z
ZENTALIS PHARMACEUTICALS LLC
NASDAQ: ZNTL (Zentalis Pharmaceuticals, Inc.)
最近更新时间: 3小时之前3.11
0.03 (0.97%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Zentalis Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-2.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -2.00 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.58% |
| 机构持股比例 | 80.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| 5Am Venture Management, Llc | 30 Jun 2026 | 3,947,913 |
| Squadron Capital Management Llc | 30 Jun 2026 | 3,700,000 |
| Acadian Asset Management Llc | 30 Jun 2026 | 2,681,900 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 1,483,500 |
| Opaleye Management Inc. | 30 Jun 2026 | 1,412,656 |
| Orbimed Advisors Llc | 30 Jun 2026 | 1,390,576 |
| Decheng Capital Llc | 30 Jun 2026 | 1,323,327 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合